Competitive polymerase chain reaction (PCR) is a quantitative adaption of the PCR method in which a known number of copies of a synthetic RNA (2,5,11) or DNA (4,6,9) is co-amplified with the target sample in the same reaction tube. Perhaps the most critical step in quantitative PCR analysis is the introduction of accurately calibrated and consistent amounts of exogenous standards to the PCR tubes. However, highly diluted competitor preparations, which are required widely, include the possibility of distinct nonspecific interactions between standard nucleic acids and the storage tube wall and possible elevated degradation. Both of these factors may strongly influence the quality of results. Therefore, most of the manufacturers and suppliers advise using only freshly prepared competitor solutions, although pipetting inaccuracies are more frequent.
INTRODUCTION
Competitive polymerase chain reaction (PCR) is a quantitative adaption of the PCR method in which a known number of copies of a synthetic RNA (2, 5, 11) or DNA (4, 6, 9) is co-amplified with the target sample in the same reaction tube. Perhaps the most critical step in quantitative PCR analysis is the introduction of accurately calibrated and consistent amounts of exogenous standards to the PCR tubes. However, highly diluted competitor preparations, which are required widely, include the possibility of distinct nonspecific interactions between standard nucleic acids and the storage tube wall and possible elevated degradation. Both of these factors may strongly influence the quality of results. Therefore, most of the manufacturers and suppliers advise using only freshly prepared competitor solutions, although pipetting inaccuracies are more frequent.
Therefore, the aim of this work was to select optimal techniques for standard calibration and reliable conditions for storage of highly diluted competitors, thus preventing quantitation artifacts by unstable preparations. To adopt the method for clinical routine analysis, an optimized protocol is proposed to determine relative levels of mRNA coding for multidrug resistance-associated protein (MRP), which is associated in multidrug resistance (3) and glyceraldehyde-3-phosphate dehydrogenase ( GAPDH) gene transcripts, which are frequently used for normalization of quantitative PCR results (9) .
MATERIALS AND METHODS

Cell Lines
The high-level, multidrug-resistant human T-lymphoblastoid cell line CCRF ADR5000, drug-selected by adriamycin as described earlier (7), and human skin fibroblasts were used.
RNA Isolation and cDNA Synthesis
Total RNA was isolated using RNAzol ® "B" (Tel-Test, Friendswood, TX, USA). cDNA was synthesized from 1-µ g aliquots of total RNA in a 20-µ L standard reaction mixture containing avian myeloblastosis virus (AMV) reverse transcriptase buffer (250 mM Tris-HCl, pH 8.3, 250 mM KCl, 50 mM MgCl 2 , 50 mM dithiothreitol, 2.5 mM spermidine), 5 U AMV reverse transcriptase, 0.5 mM of each dNTP (Promega, Madison, WI, USA), 10 U recombinant RNase inhibitor (AGS, Heidelberg, Germany), and 200 ng oligo(dT) (Pharmacia Biotech, Uppsala, Sweden).
Primers and DNA Competitors
Primers were designed using the automated Oligo ™ 5.0 Primer Analysis Software (National Biosciences, Plymouth, MN, USA) and available sequence information. A homologous competitor fragment developed for MRP quantitation was generated using a modified site-directed mutagenesis protocol described by Förster (6) . Briefly, the competitor fragment for the chosen PCR product was generated by PCR amplification of cDNA from the MRP-expressing CCRF ADR5000 cells with the appropriate 5 ′ primer and a 3 ′ linker primer (LP) carrying the original 3 ′ primer sequence on its 5 ′ end. Primers used in this procedure were MRP3 (5 ′ -GCTCGTCTTGTC -CTGTTTCT-3 ′ , 5 ′ primer), MRP4 (5 ′ -CTCCACCTCCTCATTCGCAT-3 ′, 3′ primer) and MRP-LP (5 ′ -MRP4-CCTTCTTCCA GTTCTTTACC-3 ′ ). A purified 355-bp fragment of the pMS1 plasmid carrying a heterologous (multifunctional) competitor DNA sequence (9) was used for GAPDH quantitation using primers hGAPDH1 (5 ′ -CGTCTTCACC ACCATGGAGA-3 ′ ) and hGAPDHrc (5 ′ -CGGCCATCAC GCCACAGTTT-3 ′ ).
Standard Competitive PCR Assay
Aliquots of reverse-transcribed RNA were amplified in 50-µ L standard PCR mixtures containing 2 µ L of each 3 ′ and 5 ′ primer (10 pmol/ µ L), 5 µ L 10 ×TaqDNA polymerase buffer (100 mM Tris-HCl, 500 mM KCl, 15 mM MgCl 2 , 0.01% [wt/vol] gelatin, pH 8.3), 1.5 U AmpliTaq ® DNA Polymerase (Perkin-Elmer, Norwalk, CT, USA) and 8 µ L dNTPs (0.2 mM each, [Promega]) using dUTP (Boehringer Mannheim, Mannheim, Germany) instead of dTTP. Amplifications were started with an initial 15-min incubation at 37°C with 0.2 U uracil-DNA glycosylase (UDG; Boehringer Mannheim) added to each reaction tube to prevent carryover contamination. A 10-min denaturation at 94°C was performed followed by manual addition of AmpliTaq DNA Polymerase at 72°C. After an initial PCR cycle to allow second-strand cDNA synthesis, aliquots of a serial dilution of the competitor fragment (appropriate 2-5 µ L vol) were added. MRP amplification was performed with 30 cycles (94°C for 30 s, 53°C for 30 s and 72°C for 1 min) and GAPDH was amplified for 20-40 cycles (94°C for 30 s, 58°C for 30 s and 72°C for 45 s) using a GeneAmp ® 9600 Thermal Cycler (Perkin-Elmer).
Purification and Storage of Competitor DNA Fragments
PCR-amplified standard fragments were purified by electrophoresis through a 2% (wt/vol) agarose gel. Ethidium bromide-stained bands were cut out, and DNA was isolated by using a Sephaglas ™Band Prep Kit (Pharmacia Biotech). The purified fragments were diluted to a final concentration of about 10 ng/ µ L with sterile water, and competitor working dilutions were prepared with water or an aqueous solution of Hin dIII-digested λ DNA (1-10 ng/ µ L; AGS, Heidelberg, Germany) used as a carrier for competitor stabilization. All solutions were stored at -20°C in 1.7-mL Multi Twist Top Vials (Sorenson Bio Science, Salt Lake City, UT, USA).
Calibration and Quantitation of DNA Fragments by HPLC
Aliquots of competitor stock solution and Low DNA Mass Ladder ™ (Life Technologies, Gaithersburg, MD, USA) composed of a mixture of six blunt-ended DNA fragments ranging from 100-2000 bp, containing 5-100 ng DNA, respectively, were chromatographed over a TSK DEAE-NPR column protected by a DEAE-NPR guard column (TosoHaas GmbH, Stuttgart, Germany). An HPLC system (Jasco Labor und Datentechnik GmbH, Gross-Umstadt, Germany) was used that consisted of a pump, low-pressure gradient former, degasser, UV/VIS detector and an autosampler (capacity: 84-well plate, suitable for 0.2-mL MicroAmp ® Reaction Tubes [PerkinElmer]). Twenty-microliter aliquots of each competitive PCR sample were applied to the column. For HPLC, a mobile phase of binary composition consisting of Buffer A (25 mM Tris-HCl, 1 M NaCl, pH 9.0) and Buffer B (25 mM Tris-HCl, pH 9.0) was used, and a discontinuous gradient program was used as described earlier (8) . Data aquisition and integration were performed with NINA Chromato-Graphic-System Software (Nuclear Interface GmbH, Mün -ster, Germany). Differences in UV absorbance resulting from the different lengths of standard and target DNA fragments were adjusted using a correction factor, determined as follows: a 10-point titration analysis was performed in duplicate with both original primers and a primer set, which was replaced for the unlabeled by a Cy5 ™-labeled 5 ′ primer. Non-fluorescent samples were analyzed by HPLC and Cy5-labeled DNA by electrophoresis through a ReadyMix gel using an ALFexpress ™ Personal DNA Sequencer (Pharmacia Biotech). Data were processed with the AlleliX V2.00.25 Fragment Analysis Software (Pharmacia Biotech). The correction factors that match the ratio of titrated cDNA amounts obtained by ALF/HPLC analysis were 0.665 for MRP and 0.4 for GAPDH.
RESULTS AND DISCUSSION
Calibration of Competitor DNA Fragments
When competitor DNA fragments used for quantitation of several cDNAs were synthesized and purified as described, recovery was 1-4 µ g DNA from 6 amplification reactions. In a representative experiment (Figure 1) , a purified heterologous 355-bp multifunctional competitor DNA fragment used for GAPDH cDNA quantitation was subjected to HPLC analysis and calibrated by a reference curve generated from a parallel run of a DNA mass ladder aliquot.
To assess the reproducibility of the calibration method, two separate preparations of the competitor fragment were independently calibrated. Standard dilutions yielding final competitor concentrations of 0.4, 2 and 4 amol per assay were prepared, and GAPDH transcripts were quantified in duplicate in a uniformly used human skin fibroblast cDNA sample. Initial cDNA amounts were calculated from the absorbance ratio of target-to-standard-derived products ( A t / A s ) following correction for UV absorbance differences. The high reproducibility of the calibration procedure was reflected by the measured cDNA concentrations (11.0 ± 0.2 and 10.5 ±0.9 amol GAPDH cDNA/ µ g reverse-transcribed RNA), which differed by only 2% from the mean value. Considering the many 
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steps required for standard fragment preparation, these differences were small. Therefore, we recommend the procedure over traditional UV-absorbance measurement (6,11) or calibration by densitometric means (4).
Effect of Carrier DNA on Competitor Preservation and Enzymatic Amplification
For these experiments, the homologous MRP standard DNA fragment was used, producing a fragment 88 bp shorter than the target. As shown earlier, the competitor allowed reliable quantitation during both exponential and plateau phases of amplification (9) . Carrier Hin dIII-digested λ DNA was added to the standard solutions to stabilize the DNA and to block nonspecific binding of DNA to the storage tube. As shown in Figure 2A , the ratio of template-to-competitor-derived products increased due to loss of competitor with increasing storage time when carrier DNA was omitted from the solution. A standard deviation (SD) of about 49% was obtained when competitor solutions were subjected to three freeze/thaw cycles and when they were stored for more than 3 weeks. Conversely, substantially improved preservation of highly dilute competitors was achieved when carrier DNA was added before freezing. This effect was more obvious when 10 ng instead of 1 ng carrier DNA per µ L competitor solution (SD ±34% vs. ± 18%) were added ( Figure 2 , B and C). Greater amounts of carrier DNA showed no further effect. SD values of about 20% are in the range of inter-assay variations observed for PCR quantitation of MRP transcripts (9) . Different slopes of the individual curves are purported to be the result of competition artifacts, which may be observed when the concentration of either target or competitor species is in great excess (5) .
To assess the integrity of highly diluted competitors following long-term storage in the presence of 10 ng/ µ L carrier DNA, MRP cDNA was quantified in a unique CCRF ADR5000 cDNA sample using freshly prepared competitor solution and a competitor dilution series that had been stored for 1 year at -20°C. cDNA concentrations were 16.8 and 16.3 zmol (i.e., 10 -21 mol) per µ g reverse-transcribed RNA (SD ± 1.5%), respectively, indicating competitor stabilization under storage conditions. The enhanced stability is rather the result of reduction in loss of DNA due to nonspecific binding to storage tubes than of degradation, e.g., by ambient UDG from bacterial infections. Therefore, the long-term storage of larger batches of highly diluted competitor DNA is possible. Consequently, the precision of transcript quantitation stretched over a long time period may be improved.
Experiments performed in such a way with stabilized competitors revealed another beneficial DNA side effect, which cannot be explained: the variability in amplification was diminished using heterologous standards, whose application is often limited by efficiency problems (9) . As shown in Figure 3 , for competitive amplification of GAPDH cDNA, the addition of 50 ng λ DNA per assay with the standard formulation may be beneficial. A nonuniform accumulation of GAPDH products may be easily converted into a uniform one, resulting in a shift from a non-horizontal to a horizontal A t / A s curve.
Contamination-Free Standard Competitive PCR Assay
An optimized amplification procedure was adopted for quantitative PCR using calibrated and stabilized doublestranded DNA competitors. If such competitors are used to assay cDNA reverse-transcribed from mRNA in a sample, the amount of template will be theoretically underestimated by a factor of 2. This discrepancy can be overcome by applying single-stranded DNA as proposed by de Kant and coworkers (4) or, alternatively, by extension of thermal cycling by one cycle before adding the standards.
Conversely, strict avoidance of contamination is an essential feature for reproducible use of competitive PCR. Cross-contamination may be efficiently prevented by replacing the great majority of dT molecules with dU and by treating the PCR mixture with 0.2 U UDG before thermocycling. UDG has been shown to retain partial activity even after extensive incubation at 95°C and applying as little as 0.1 U of enzyme per assay (10) . However, we observed negligible product degradation (<5%) following incubation of the sample at room temperature for as long as 12 h (i.e., throughout the period of automated HPLC analysis; data not shown). Therefore, effects of residual UDG activity on product ratios can be ruled out. But note that the precautions taken in this study require that dU-replaced competitors are added subsequent to UDG heat-inactivation.
In summary, we have described an optimized competitive PCR protocol. Although the approach described here is valuable in quantifying cDNA, the method does not address variability occuring during reverse transcription. Therefore, data normalization according to reference gene transcripts measured by the same procedure and expressed in the same sample, e.g., GAPDH cDNA, is required (9). To measure absolute cDNA amounts, the method is further limited by the requirement of a factor necessary to correct for UV absorbance differences with regard to different lengths of PCR products. This type of correction is unnecessary when using PCR enzymelinked immunosorbent assay (ELISA) technology (1, 9) . The development of assays for simultaneous discrimination between homologous PCR products differing by at least one nucleotide is now in progress.
